Arcutis Swings to Profit on Zoryve Sales Surge, Cash Dips

TL;DR

**ARQT finally hit quarterly profit thanks to Zoryve, but watch that cash burn and accumulated deficit – it's not out of the woods yet.**

AI Summary

Arcutis Biotherapeutics, Inc. (ARQT) reported a significant increase in product revenue, reaching $99.219 million for the three months ended September 30, 2025, a substantial rise from $44.755 million in the same period of 2024. Total revenues for the nine months ended September 30, 2025, were $246.569 million, up from $125.182 million in 2024. The company achieved a net income of $7.410 million for the third quarter of 2025, a notable turnaround from a net loss of $41.537 million in Q3 2024. Despite this, the nine-month period still shows a net loss of $33.536 million. Operating expenses increased to $90.693 million for the quarter, primarily driven by selling, general, and administrative expenses of $62.404 million. The company's cash and cash equivalents decreased from $71.335 million at December 31, 2024, to $47.120 million at September 30, 2025, and it had an accumulated deficit of $1,155.5 million. Strategic outlook includes continued commercialization of ZORYVE products, with recent FDA approvals for ZORYVE foam for plaque psoriasis (May 2025) and ZORYVE cream 0.05% for atopic dermatitis in young children (October 2025).

Why It Matters

Arcutis's shift to quarterly net income, driven by strong ZORYVE product sales, signals a potential turning point for investors in this commercial-stage biopharmaceutical company. The expanded FDA approvals for ZORYVE across various dermatological conditions, including plaque psoriasis and atopic dermatitis, enhance its competitive position against other dermatology players. However, the continued overall net loss for the nine-month period and declining cash reserves highlight ongoing financial pressures. Employees and customers benefit from the successful commercialization and broader availability of ZORYVE, but the company's long-term financial stability remains a key concern for sustained growth and innovation in the competitive dermatology market.

Risk Assessment

Risk Level: medium — While Arcutis achieved a quarterly net income of $7.410 million, it still reported a significant accumulated deficit of $1,155.5 million as of September 30, 2025. Cash and cash equivalents decreased from $71.335 million to $47.120 million, and net cash used in operating activities was $31.810 million for the nine months, indicating ongoing liquidity management challenges despite revenue growth.

Analyst Insight

Investors should monitor ARQT's ability to sustain quarterly profitability and improve cash flow from operations. The strong product revenue growth is positive, but the substantial accumulated deficit and declining cash reserves suggest continued reliance on future financing or further sales acceleration to achieve long-term financial health. Consider if the ZORYVE pipeline can offset the current cash burn.

Financial Highlights

debt To Equity

1.35

revenue

$246,569,000

operating Margin

-12.4%

total Assets

$370,977,000

total Debt

$108,498,000

net Income

$7,410,000

eps

$0.06

gross Margin

89.7%

cash Position

$47,120,000

revenue Growth

+97.0%

Revenue Breakdown

Key Numbers

• $99.219M — Product Revenue, Net (Q3 2025) (Increased from $44.755M in Q3 2024, a 121.7% increase.)
• $7.410M — Net Income (Q3 2025) (Turnaround from a net loss of $41.537M in Q3 2024.)
• $246.569M — Total Revenues (Nine Months 2025) (Increased from $125.182M in Nine Months 2024, a 97% increase.)
• $1,155.5M — Accumulated Deficit (September 30, 2025) (Indicates significant historical losses despite recent quarterly profit.)
• $47.120M — Cash and Cash Equivalents (September 30, 2025) (Decreased from $71.335M at December 31, 2024, highlighting cash burn.)
• $31.810M — Net Cash Used in Operating Activities (Nine Months 2025) (Reduced from $111.410M in Nine Months 2024, showing improved operational efficiency.)
• $0.06 — Diluted EPS (Q3 2025) (Positive EPS compared to -$0.33 in Q3 2024.)
• 120,288,146 — Common Stock Shares Outstanding (September 30, 2025) (Increased from 117,848,033 at December 31, 2024, due to stock options and RSU vesting.)

Key Players & Entities

• Arcutis Biotherapeutics, Inc. (company) — commercial-stage biopharmaceutical company
• ZORYVE (company) — approved product for dermatological diseases
• FDA (regulator) — U.S. Food and Drug Administration
• Health Canada (regulator) — Canadian regulatory body
• Cowen and Company, LLC (company) — sales agent for ATM program
• $99.219 million (dollar_amount) — product revenue for Q3 2025
• $7.410 million (dollar_amount) — net income for Q3 2025
• $1,155.5 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $47.120 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $31.810 million (dollar_amount) — net cash used in operating activities for nine months ended September 30, 2025

FAQ

Risk Factors

• Sustained Cash Burn and Accumulated Deficit [high — financial]: The company has an accumulated deficit of $1,155.5 million as of September 30, 2025. Cash and cash equivalents decreased from $71.3 million at the end of 2024 to $47.1 million, indicating ongoing cash consumption.
• Dependence on Product Success [high — market]: Revenue growth is heavily reliant on the successful commercialization and market adoption of ZORYVE products. Any setbacks in sales or market penetration could significantly impact financial performance.
• Regulatory Approval and Compliance [medium — regulatory]: While recent FDA approvals for ZORYVE are positive, the company must continue to navigate complex regulatory pathways for future products and maintain compliance with post-market requirements.
• Increasing Operating Expenses [medium — operational]: Operating expenses rose to $90.7 million in Q3 2025, primarily due to a 5.8% increase in SG&A expenses to $62.4 million. Continued increases in these costs could pressure profitability.
• Debt Obligations [medium — financial]: The company has $107.5 million in long-term debt and a current portion of $1 million. Managing these debt obligations alongside operational expenses is crucial.

Industry Context

Arcutis Biotherapeutics operates in the competitive dermatology and immunology sector, focusing on treatments for inflammatory skin conditions. The market is characterized by significant R&D investment, stringent regulatory oversight, and the need for innovative therapies to address unmet patient needs. Key trends include the development of novel drug delivery systems and targeted therapies.

Regulatory Implications

The company's success is tied to its ability to obtain and maintain FDA approvals for its products. Post-market surveillance and adherence to manufacturing and marketing regulations are critical. Any adverse regulatory actions or delays in approvals could significantly impact revenue and market position.

What Investors Should Do

1. Monitor SG&A expense growth
2. Assess cash burn rate and runway
3. Track ZORYVE sales performance
4. Evaluate impact of new product approvals

Key Dates

• 2025-05-01: FDA Approval for ZORYVE foam for plaque psoriasis — Expands the product portfolio and market reach for a key revenue driver.
• 2025-10-01: FDA Approval for ZORYVE cream 0.05% for atopic dermatitis in young children — Further broadens the application of ZORYVE and targets a new patient demographic.
• 2025-09-30: End of Q3 2025 — Reporting period for the financial results, showing a significant increase in product revenue and a return to quarterly net income.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of cash position and other balance sheet items.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company has historically operated at a loss, despite recent quarterly profitability.)

Product revenue, net

Revenue generated from the sale of the company's pharmaceutical products after deducting allowances, returns, and discounts. (Key indicator of commercial success for Arcutis's marketed drugs.)

Operating expenses

Costs incurred in the normal course of business, excluding cost of goods sold, typically including R&D and SG&A. (Shows the company's investment in growth and operations, which has increased year-over-year.)

Cash and cash equivalents

Highly liquid investments with maturities of three months or less from the date of purchase. (Represents the company's immediate liquidity and ability to fund operations.)

Diluted EPS

Earnings per share calculated by dividing net income by the weighted-average number of outstanding common shares, including dilutive potential common shares. (Measures profitability on a per-share basis, showing a positive trend for the quarter.)

Year-Over-Year Comparison

Compared to the prior year, Arcutis Biotherapeutics has demonstrated substantial top-line growth, with total revenues for the nine months ended September 30, 2025, increasing by 97.0% to $246.6 million from $125.2 million in 2024. This revenue surge has led to a significant improvement in profitability, with the company achieving net income of $7.4 million in Q3 2025, a stark contrast to a net loss of $41.5 million in the same period of 2024. However, operating expenses have also risen, and the company's cash position has declined, underscoring the ongoing need for careful financial management despite the positive revenue and net income trends.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 ARQT The Nasdaq Global Select Market

Filing Documents

• arqt-20250930.htm (10-Q) — 1093KB
• exhibit311ceoq32025.htm (EX-31.1) — 10KB
• exhibit312cfoq32025.htm (EX-31.2) — 10KB
• exhibit321ceocfoq32025.htm (EX-32.1) — 7KB
• 0001787306-25-000144.txt ( ) — 6433KB
• arqt-20250930.xsd (EX-101.SCH) — 49KB
• arqt-20250930_cal.xml (EX-101.CAL) — 64KB
• arqt-20250930_def.xml (EX-101.DEF) — 201KB
• arqt-20250930_lab.xml (EX-101.LAB) — 628KB
• arqt-20250930_pre.xml (EX-101.PRE) — 419KB
• arqt-20250930_htm.xml (XML) — 869KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "forecasts," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to statements regarding our future results of operations and financial position, industry and business trends, stock compensation, business strategy, plans, market growth, commercialization of approved products, and our objectives for future operations. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed in Part II, Item 1A, "Risk Factors" in this Quarterly Report on Form 10-Q for the q

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Income ( Loss ) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6 Item 3.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 34 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 37 Item 6. Exhibits 38

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ARCUTIS BIOTHERAPEUTICS, INC. Condensed Consolidated Balance Sheets (In thousands, except share and par value) (unaudited) September 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 47,120 $ 71,335 Restricted cash 308 617 Marketable securities 143,948 156,620 Trade receivables, net 115,116 73,066 Inventories 22,419 14,526 Prepaid expenses and other current assets 20,313 19,656 Total current assets 349,224 335,820 Property, plant, and equipment, net 1,215 1,041 Intangible assets, net 15,375 9,479 Operating lease right-of-use asset 4,567 1,953 Other assets 596 596 Total assets $ 370,977 $ 348,889 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,795 $ 14,220 Current portion of long-term debt, net 1,000 — Accrued and other current liabilities 92,975 66,793 Total current liabilities 99,770 81,013 Operating lease liability, long-term 5,276 2,562 Long-term debt, net 107,498 107,203 Other long-term liabilities 360 570 Total liabilities 212,904 191,348 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value; 300,000,000 shares authorized at September 30, 2025 and December 31, 2024; 120,288,146 and 117,848,033 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 12 12 Additional paid-in capital 1,313,602 1,279,479 Accumulated other comprehensive loss ( 62 ) ( 7 ) Accumulated deficit ( 1,155,479 ) ( 1,121,943 ) Total stockholders' equity 158,073 157,541 Total liabilities and stockholders' equity $ 370,977 $ 348,889 See accompanying notes to the condensed consolidated financial statements. 1 Table of Contents ARCUTIS BIOTHERAPEUTICS, INC. Condensed Consolidated Statements of Op

View Full Filing

View this 10-Q filing on SEC EDGAR